REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition.
On August3, 2017, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended June30, 2017. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.
The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release, dated August3, 2017, Reporting Second Quarter 2017 Financial and Operating Results.
REGENERON PHARMACEUTICALS INC ExhibitEX-99.1 2 exhibit991q22017.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2017 Financial and Operating Results•Second quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 11% to $919 million versus second quarter 2016•Second quarter 2017 EYLEA global net sales(1) increased 11% to $1.46 billion versus second quarter 2016•Raised estimated full year 2017 EYLEA U.S. net sales growth guidance to approximately 10% over 2016•Kevzara® (sarilumab) approved by FDA and European Commission for adults with moderately to severely active rheumatoid arthritisTarrytown,…To view the full exhibit click here
About REGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.
